



Frontier Biotech chooses Novasep HPLC chromatography columns and skids for peptide purification on its Nanjing (China) site



Lyon, France, July 9, 2020 – Novasep, a leading supplier of services and technologies for the life sciences industry, announces Frontier Biotechnologies Inc. (“Frontier Biotech”) chooses Novasep [Prochrom](#)® HPLC chromatography columns and skids for its Nanjing (China) site.

Frontier Biotech is a global biopharmaceutical company whose core competence is to develop novel anti-viral and long-acting drug products.

Founded by Dr. Xie in 2013, Frontier Biotech's first commercial product (Aikening®) was approved by NMPA, which is the counterpart of FDA in China, in May 2018 through a priority review process and has gained accelerated approval. Aikening® is a new chemical entity (NCE) with a novel molecular mechanism of action, which is the first novel AIDS drug in China and the first long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS in the world.

“Aikening® is effective against most HIV-1 strains including drug-resistant strains, administered by intravenous infusion on a weekly basis. It is a peptide drug with a good safety profile and no predictable drug-drug interactions” said Dr. CJ Wang, CEO of Frontier Biotech. “Because the products and the production stability are closely related to the stability and robustness of the equipment, we hope we can produce Aikening® API with highest quality with Novasep [Prochrom](#)® [equipment](#) and meet the requirements of domestic and foreign markets, giving patients best quality service.”

Novasep offers a range of products and solutions that cater for all stages and scales of operation, from the development phase to large-scale commercial production. [Prochrom](#)® [HPLC columns and skids](#) are designed to purify APIs, biologics, peptides, oligonucleotides, insulin, cannabinoids, amongst others.





*“With 30 years’ experience in developing, using and supplying preparative HPLC systems, more than 1,500 **Prochrom**[®] columns are purifying peptides, APIs and intermediates every day, all around the world. These equipments fit particularly well with Frontier’s strategy to bring innovative drug products to patients globally” said Dr. Michel Spagnol, Chairman & CEO of Novasep Group.*

The introduction of innovative technologies for the pharmaceutical and biopharmaceutical markets is a key element of the Rise-2 strategy deployed by Novasep Group in 2017 and aiming at doubling its profitability by 2022.

For press information, click here: <https://www.novasep.com/press-release-about-novasep.html>

Contacts

Novasep
Laure Saloin
Communication Project Manager
+33 7 77 94 37 52

Frontier Biotech
Matthew Ma
Global BD senior manager
(+86) 13524102369

About Frontier Biotech

Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.

For more information on Frontier Biotech, please visit <http://www.frontierbiotech.com/en/>

About Novasep

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for the life science sector, as well as of molecules for pharmaceutical, biopharmaceutical and other fine chemical applications. From the development stage right up to industrial scaling, we provide a complementary range of GMP equipment and services for purification. Modular and customizable, our chromatography equipment can integrate seamlessly into any process.

For more information about Novasep, visit <http://www.novasep.com>

 Follow [Novasep](#) on LinkedIn